[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rcc-renal-cell-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rcc-renal-cell-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,77,107,129,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100614313","phase-2-iparomlimab-and-tuvonralimab-injection-in-combination-with-lenvatinib-or-axitinib-for-the-treatment-of-locally-advanced-or-metastatic-clear-cell-renal-cell-carcinoma-that-has-failed-first-line-systemic-therapy-100614313",false,"NCT07277972","Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy","An Open-Label, Single-Arm, Multicenter, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy","Inclusion Criteria:\n\n* Age at Diagnosis: ≥18 years.\n* Histologically confirmed locally advanced or metastatic clear cell renal cell carcinoma.\n* Disease progression or intolerance during or following first-line systemic therapy.\n* ECOG Performance Status: 0-1.\n* At least one measurable lesion as defined by RECIST v1.1.\n* Life expectancy ≥12 weeks.\n* Adequate bone marrow function: White blood cell count \\> 4.0×10⁹\u002FL, Hemoglobin \\> 90 g\u002FL, Platelet count \\> 100×10⁹\u002FL.\n* Adequate hepatic and renal function: Total bilirubin ≤ 1.5 × ULN; Aspartate aminotransferase and\u002For Alanine aminotransferase ≤ 2.5 × ULN; Alkaline phosphatase ≤ 2.5 × ULN; Serum creatinine ≤ 1.5 × ULN.\n* Adequate coagulation function: International Normalized Ratio (INR) ≤1.5 × ULN, Activated Partial Thromboplastin Time (APTT) ≤1.5 × ULN.\n* The patient must provide signed informed consent and be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures as specified in the study protocol.\n* Female subjects of childbearing potential must agree to use reliable contraceptive methods (e.g., condoms, prescribed oral contraceptives taken regularly) from screening until 1 year after the end of treatment.\n\nExclusion Criteria:\n\n* Allergy to any component of macromolecular protein preparations; contraindications or hypersensitivity to any ingredient of Iparomlimab and Tuvonralimab Injection, Lenvatinib, or Axitinib.\n* Major surgery within 28 days prior to the first dose (excluding diagnostic laparoscopy; local surgery for isolated lesions is acceptable).\n* Positive Hepatitis B surface antigen (HBsAg) with HBV DNA \\>1×10³ copies\u002FmL, or positive anti-Hepatitis C virus (HCV) antibody.\n* Positive anti-HIV antibody or a diagnosis of Acquired Immunodeficiency Syndrome (AIDS).\n* Active, known, or suspected autoimmune disease (including but not limited to uveitis, enteritis, hepatitis, pituitary disorders, nephritis, vasculitis, systemic lupus erythematosus, hyperthyroidism, hypothyroidism, asthma requiring bronchodilator therapy). Exceptions include type I diabetes mellitus, hypothyroidism requiring hormone replacement therapy only, and skin disorders not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia).\n* Renal failure requiring hemodialysis or peritoneal dialysis.\n* History of interstitial lung disease (ILD) or pneumonitis requiring oral or intravenous steroids within the past year; administration of Vancomycin within the past month.\n* Chronic systemic glucocorticoid therapy (at a dose equivalent to ≥10 mg prednisone daily) or any other form of immunosuppressive therapy. Subjects using inhaled or topical corticosteroids are eligible.\n* Uncontrolled cardiac disease, such as: 1) Heart failure, NYHA class ≥ II; 2) Unstable angina; 3) Myocardial infarction within the past year; 4) Supraventricular or ventricular arrhythmia requiring treatment or intervention.\n* Thromboembolic events within 6 months prior to the start of study treatment, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), or pulmonary embolism, etc.\n* Known central nervous system metastases.\n* Urinalysis indicating urine protein ≥ +++ and confirmed 24-hour urinary protein \\>1.0 g.\n* Pregnant or lactating women (a pregnancy test should be considered for sexually active women of childbearing potential).\n* Prior or concurrent other malignancies, except for adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, and papillary carcinoma of the thyroid.\n* Active infection requiring systemic therapy within one week.\n* Administration of a live vaccine within 30 days prior to the first dose of Iparomlimab and Tuvonralimab Injection.\n* History of organ transplantation or hematopoietic stem cell transplantation.\n* Any other condition that, in the investigator's assessment, may compromise patient safety or compliance, such as severe concomitant illnesses (including psychiatric disorders) requiring prompt treatment, severely abnormal laboratory test results, or the presence of other psychological, familial, or sociogeographic factors posing high-risk.","ALL","18 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The primary objective is to evaluate the improvement in Objective Response Rate (ORR) achieved with Iparomlimab and Tuvonralimab Injection (QL1706, an Anti-PD-1\u002FCTLA-4 Combined Antibody) in combination with Lenvatinib or Axitinib, in patients with locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have failed first-line systemic therapy.",[26],"RCC, Renal Cell Cancer",[28,29,30],"lparomlimab and Tuvonralimab Injection","Lenvatinib","Axitinib","NOT_YET_RECRUITING","2025-11-30",{"date":34,"type":35},"2025-12-11","ACTUAL",{"date":37,"type":20},"2026-02-15",{"date":39,"type":20},"2031-08-31",{"name":41,"class":42},"Tianjin Medical University Cancer Institute and Hospital","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100611913","neutrophil-biomarker-test-for-predicting-clinical-benefit-from-immunotherapy-based-on-flow-cytometry-analysis-100611913","NCT07246759","Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis","NEUTROFLOW: Development and Validation of a Pan-cancer Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis of Blood Samples","NEUTROFLOW","Inclusion Criteria:\n\n• Patients newly diagnosed with advanced-stage\u002Fmetastatic NSCLC, melanoma, HNSCC, RCC, or TNBC, who are due to receive first-line treatment with a PD-(L)1 inhibitor, either as monotherapy or in combination with other agents, according to current standard-of-care regimens, including (but not limited to) the following approved options: NSCLC. Monotherapy: Pembrolizumab, Atezolizumab, Cemiplimab. Combination: Pembrolizumab + chemotherapy; Nivolumab + Ipilimumab; Cemiplimab + chemotherapy; Atezolizumab + chemotherapy + Bevacizumab.\n\nMelanoma. Monotherapy: Nivolumab, Pembrolizumab. Combination: Nivolumab + Ipilimumab; Nivolumab + Relatlimab.\n\nHNSCC. Monotherapy: Pembrolizumab, Cemiplimab. Combination: Pembrolizumab + chemotherapy.\n\nRCC. Combination only: Nivolumab + Ipilimumab; Nivolumab + Cabozantinib; Pembrolizumab + Lenvatinib or Axitinib; Avelumab + Axitinib.\n\nTNBC. Combination only: Pembrolizumab + chemotherapy.\n\n* Male or female aged at least 18 years\n* ECOG PS: 0\u002F1-2\n* Normal hematologic, renal and liver function:\n\nAbsolute neutrophil count \\> 1500\u002Fmm³ Platelets \\> 100,000\u002Fmm³ Hemoglobin \\> 9 g\u002FdL Creatinine concentration ≤ 1.4 mg\u002FdL, or creatinine clearance \\> 40 mL\u002Fmin, Total bilirubin \\\u003C 1.5 mg\u002FdL ALT + AST levels ≤ 3 times above the upper normal limit\n\nExclusion Criteria:\n\n* Any concurrent and\u002For other active malignancy that has required systemic treatment within 2 years of the first dose of treatment.\n* For NSCLC: presence of activating EGFR, ALK, ROS1, RET, NTRK alterations linked to an approved first-line targeted drug.",{"count":52,"type":20},600,"OBSERVATIONAL","The NeutroFlow study is a multi-center clinical trial designed to develop a computational model that converts flow cytometry results into a prediction of clinical benefit. The study analyzes Ly6Ehi neutrophils in biological samples from patients treated with immune checkpoint inhibitors to evaluate their likelihood of benefiting from treatment. Blood samples are collected prior to treatment and used to support the ongoing development of the algorithm.",[56,57,58,26,59],"Non Small Cell Lung Cancer (NSCLC)","Melanoma (Skin Cancer)","Triple Negative Breast Cancer (TNBC)","HNSCC",[61,62,63,64,65],"Immunotherapy","Biomarker","Neutrophils","Flow Cytometry","Immune checkpoint inhibitor","2025-11-20",{"date":68,"type":35},"2025-11-24",{"date":70,"type":20},"2025-11-15",{"date":72,"type":20},"2028-05-30",{"name":74,"class":75},"OncoHost Ltd.","INDUSTRY",3,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100607598","comparison-of-outcomes-and-surgical-time-between-cortical-and-medullary-suture-vs-medullary-only-suture-cortex-clinical-trial-100607598","NCT07190638","Comparison of Outcomes and Surgical Time Between Cortical and Medullary Suture vs. Medullary-Only Suture: Cortex Clinical Trial","Comparison of Outcomes and Surgical Time Between Cortical and Medullary Suture vs. Medullary-Only Suture: Cortex Clinical Trial, From 2025 to 2027","CORTEX","Inclusion Criteria:\n\n* Diagnosis of renal mass confirmed by computed tomography (CT) or magnetic resonance imaging (MRI)\n* Indication for partial nephrectomy\n* Written informed consent\n* Expected survival of at least 6 months\n* Eastern Cooperative Oncology Group (ECOG) score performance status ≤ 1\n* Negative serum or urine pregnancy test within 24 hours before surgery for women of childbearing potential\n* Recovery from any prior therapy-related toxicity to grade 1 or better\n* If a biopsy has been performed, pathology consistent with renal cell carcinoma (RCC)\n\nExclusion Criteria:\n\n* Solitary kidney\n* Multiple or bilateral renal masses if more than one mass is operated on simultaneously or within less than 4 months\n* Hepatic or renal toxicity grade ≥ 2 with glomerular filtration rate (GFR) \\\u003C 30 according to Common Terminology Criteria for Adverse Events (CTCAE v4)\n* Bleeding diathesis\n* Inability to maintain anticoagulation for surgery\n* Participation in another experimental trial simultaneously or within 30 days prior to enrollment\n* Significant acute or chronic medical, neurological, or psychiatric condition that could compromise safety, limit study completion, or impair study objectives in the opinion of the Principal Investigator",{"count":86,"type":20},80,[88],"NA","Renal function preservation is a growing concern in the surgical management of kidney tumors, particularly with the rise in chronic kidney disease worldwide. Recent surgical innovations have focused on modifying renorrhaphy techniques to minimize renal damage. Emerging evidence suggests that omitting cortical suturing may reduce operative time, blood loss, and renal parenchymal loss without increasing major complications. This randomized controlled trial aims to compare outcomes between medullary-only and combined cortical-medullary suture techniques during robot-assisted partial nephrectomy, with the goal of identifying the approach that best balances functional preservation and surgical safety.",[26],[92,93,94,95],"Partial Nephrectomy","Robot-assisted","MEDULLARY SUTURE","MEDULLARY-ONLY SUTURE","RECRUITING","2025-09-20",{"date":99,"type":35},"2025-09-24",{"date":101,"type":35},"2025-07-23",{"date":103,"type":20},"2027-05-31",{"name":105,"class":42},"Brazilian Institute of Robotic Surgery",2,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100585940","prospective-study-on-the-safety-and-efficacy-of-robot-assisted-laparoscopic-partial-nephrectomy-with-renal-artery-off-clamp-in-the-treatment-of-ct1-renal-tumors-100585940","NCT06908902","Prospective Study on the Safety and Efficacy of Robot-Assisted Laparoscopic Partial Nephrectomy With Renal Artery Off-Clamp in the Treatment of cT1 Renal Tumors","Inclusion Criteria:\n\n* Imaging examination confirms a T1 renal tumor (including T1a and T1b), and the investigator deems partial nephrectomy to be beneficial.\n* Age ranges from 18 to 90 years.\n* No history of severe kidney disease or autoimmune disorders.\n* Cardiopulmonary function indicates the ability to tolerate major abdominal surgery.\n* ECOG performance status score is 0 or 1.\n* Willingness to undergo zero-ischemia partial nephrectomy and able to provide written informed consent, understanding and agreeing to comply with the study requirements and evaluation schedule.\n\nExclusion Criteria:\n\n* Imaging assessment shows a tumor stage of ≥T2.\n* Imaging indicates that the tumor is located in the renal pelvis or is a Wilms' tumor, etc.\n* The investigator considers the patient unsuitable for partial nephrectomy.\n* Major surgery or significant trauma occurred within 28 days prior to enrollment.\n* Live vaccine received within 28 days prior to enrollment.\n* Severe chronic or active infections requiring systemic antibacterial, antifungal, or antiviral treatment occurred within 14 days prior to enrollment.\n* Any traditional Chinese medicine or herbal supplements for cancer treatment taken within 14 days prior to enrollment.\n* Participation in any other clinical trials.","80 Years",{"count":115,"type":20},60,[88],"Renal tumors are common urological cancers, with over 430,000 new cases and more than 170,000 deaths globally in 2020. In China, renal cancer ranks third among urological malignancies, with an increasing incidence. Risk factors include smoking, obesity, hypertension, and family history. Surgery, including partial nephrectomy and radical nephrectomy, is the primary treatment. According to AJCC staging, tumors ≤7 cm confined to the kidney are classified as T1 stage. Studies show no significant difference in cancer-specific survival between partial nephrectomy and radical nephrectomy for T1 tumors, and partial nephrectomy preserves renal function, reducing the risk of metabolic and cardiovascular diseases. Therefore, European guidelines recommend partial nephrectomy for cT1a-b tumors.\n\nPartial nephrectomy can be performed via open surgery, laparoscopy, or robotic assistance, each with pros and cons. Robotic or laparoscopic approaches have less blood loss and shorter hospital stays compared to open surgery. A 7-year follow-up shows no significant difference in oncological outcomes. The surgical goal is to remove the tumor with negative margins while preserving normal renal tissue. Factors such as preoperative renal function, ischemia time, extent of normal tissue resection, blood loss, and suturing technique affect postoperative renal function.\n\nRenal artery clamping is often required during partial nephrectomy to improve visibility, but it leads to ischemia-reperfusion injury, so minimizing damage is crucial. Controlling warm ischemia time is an effective strategy, with guidelines recommending ischemia time under 30 minutes. Studies show that continuous or knotless suturing techniques reduce ischemia time and blood loss. Additionally, minimizing the ischemic area helps protect renal function. Our center explored branch renal artery clamping, which, although increasing ischemia time, better protects kidney function. A study showed a smaller decline in glomerular filtration rate (GFR) with branch clamping compared to conventional clamping.\n\nGill et al. reported a \"zero-ischemia\" technique using controlled hypotension and selective clamping of higher-level renal artery branches, showing no significant change in serum creatinine or GFR. However, both renal artery clamping techniques cause ischemia-reperfusion injury, affecting renal function. A study of robotic-assisted partial nephrectomy found that 20.2% of patients had worsened chronic kidney disease (CKD) staging, with statistically significant differences in preoperative and postoperative GFR and CKD staging.\n\nFor patients with solitary or functionally solitary kidneys, or those with comorbidities like hypertension or diabetes, renal artery clamping may worsen acute renal dysfunction and increase the risk of long-term kidney failure. Avoiding renal artery clamping may reduce ischemia-reperfusion injury, but its safety and efficacy remain unclear.\n\nA retrospective study of 537 solitary kidney patients undergoing open surgery with different vascular management strategies (no clamping, warm ischemia, and cold ischemia) showed that the risk of renal failure was lower in patients without ischemia. While this study focused on open surgery, it raises the question of whether zero-ischemia partial nephrectomy is feasible in minimally invasive surgery. A study on 141 renal angiomyolipoma patients using a zero-ischemia technique showed no significant change in GFR. However, this method may not be suitable for malignant tumors.\n\nthe investigators aims to evaluate whether robotic-assisted laparoscopic partial nephrectomy using a zero-ischemia technique for cT1 renal tumors can better protect renal function, reduce postoperative complications, and not affect oncological outcomes.",[26,92],"2025-04-01",{"date":121,"type":35},"2025-04-03",{"date":123,"type":35},"2024-12-01",{"date":125,"type":20},"2027-12-31",{"name":127,"class":42},"The First Affiliated Hospital with Nanjing Medical University",1,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":140,"conditions":141,"keywords":150,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":106},"100583992","phase-1-a-phase-i-study-of-lxp1788-injection-with-advanced-solid-tumors-100583992","NCT06883539","A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.","A Phase I Open-label Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LXP1788 Injection in Patients with Advanced Solid Tumors.","Inclusion Criteria:\n\n1. Written (signed) Informed Consent.\n2. Male or female ≥ 18 years old.\n3. Life expectancy \\> 8 weeks.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n5. A histologically or cytologically confirmed, advanced solid tumor that is refractory to currently available therapies or for which no effective treatment is available.\n6. Measurable disease per RECIST 1.1.\n7. Willing to have a tumor biopsy or having tissue sample from a previous biopsy available in the tissue bank for analysis that had been collected in the past 3 years.\n\nExclusion Criteria:\n\n1. Significant concurrent medical diseases, such as congestive heart failure, unstable angina, acute or recent myocardial infarction (\\\u003C 6 months before enrollment), COPD with frequent exacerbations, uncontrolled hypertension (systemic blood pressure \\>= 160 mmHg and\u002For diastolic blood pressure \\>= 100 mmHg with or without anti-hypertensive medication), recent CVA (\\\u003C 6 months before enrollment), or active infection which requires treatment withintravenous antibiotics.\n2. Patients with symptomatic CNS metastases who are neurologically unstable, receiving radiotherapy for the CNS lesion, or requiring increasing dose of steroids to control their CNS disease.\n\n   Asymptomatic patients with metastatic brain disease who have been on a stable dose of steroids for less than 14 days prior to screening.\n3. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:\n\n   Bone marrow:\n   * Absolute neutrophil count (ANC) \\\u003C 1.5 x 10\\^9\u002FL\n   * Platelet count \\\u003C 100 x 10\\^9\u002FL\n   * Hemoglobin \\\u003C 9 g\u002FdL\n   * Having had a blood transfusion within 2 weeks of screening date is also not allowed.\n\n   Hepatic:\n   * Total bilirubin \\> 1.5 x ULN\n   * AST and ALT \\> 3 x ULN if no liver metastases\n   * AST and ALT \\> 5 x ULN in the presence of liver metastases\n\n   Renal:\n\n   ⚫ Estimated creatinine clearance (CrCL) \\\u003C 60 mL\u002Fmin per the Cockcroft and Gault formula\n4. Known history of human immunodeficiency virus (HIV)-1 or -2 infection.\n5. Psychiatric disorders that would compromise the patient's compliance or ability to give consent.\n6. Major surgical intervention within 4 weeks of the first dose of LXP1788 Injection or with ongoing postoperative complications.\n7. Toxicities from any prior therapy, surgery, or radiotherapy that did not resolve to grade 0 or 1 as per the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, with the exception of alopecia, skin hyperpigmentation or hypopigmentation.\n8. Underlying medical conditions that, in the investigator's opinion, will make the administration of LXP1788 Injection hazardous or obscure the interpretation of toxicities or adverse events.\n9. Exposure to any other investigational or commercial anti-cancer agents or curative therapies within 28 days or 5 half-lives (whichever is shorter), before the first dose of LXP1788 Injection. Exposure to radiation therapy for non-curative purposes or pain control may be permitted under the judgement of the investigator.\n10. Judgment by the investigator that the patient should not participate in the study because the patient is unlikely to comply with study procedures, restrictions, or requirements.\n11. Pregnancy or breast feeding.\n12. Women or men of childbearing potential not willing to use effective means of contraception.\n13. Positive test for hepatitis B (HBsAg) or hepatitis C (positive HCV antibody with detectable HCV RNA).\n14. History of allergic reactions to any component of LXP1788 Injection.",{"count":137,"type":20},24,[139],"PHASE1","A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LXP1788 Injection in patients with advanced solid tumor.\n\nPatients with advanced solid tumors that are refractory to currently available therapies or for whom no effective treatment is available will be selected.\n\nThe main questions it aims to answer are:\n\n1. To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of LXP1788 Injection\n2. To evaluate the pharmacokinetics (PK) of LXP1788 Injection",[142,143,144,145,146,147,148,26,149],"Solid Tumor Malignancies, Cancer","Solid Cancers","Solid Tumor Cancer","Solid Tumor, Unspecified, Adult","Solid Tumour","Solid Tumors Refractory to Standard Therapy","HCC - Hepatocellular Carcinoma","Pancreas Cancer",[151,152,153,154,155,156,157,158,159,160],"Phase 1","LXP1788","LAUNXP","DBPR114-101","solid tumor","cancer","Hepatocellular carcinoma","Pancrease Cancer","Renal Cell Carcinoma","Tyrosine kinase inhibitor","2025-03-12",{"date":163,"type":35},"2025-03-19",{"date":165,"type":35},"2024-12-31",{"date":167,"type":20},"2028-06-30",{"name":169,"class":75},"LaunXP Biomedical Co., Ltd.",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":179,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":128},"100575254","a-study-evaluating-the-value-of-68ga-nota-rccb6-pet-imaging-for-targeting-cd70-in-the-clinical-staging-therapeutic-evaluation-and-restaging-of-renal-cell-carcinoma-and-comparing-it-with-68ga-psma-petct-imaging-100575254","NCT06769893","A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET\u002FCT Imaging","A Prospective, Open-label, Single-center Study of CD70-Specific PET\u002FCT Imaging for Non-invasive Diagnosis of Renal Cell Carcinoma","Inclusion Criteria:\n\n\\- The subject or legal guardian\u002Fcaregiver must voluntarily sign the informed consent form.\n\nAges 18 to 75 years old. Patients with suspected renal cell carcinoma based on conventional imaging studies, and who undergo 68Ga-PSMA PET\u002FCT scanning.\n\nPatients with suspicious lymph nodes or distant metastases detected by conventional imaging or 68Ga-PSMA PET\u002FCT.\n\nWilling and able to follow the study protocol.\n\nExclusion Criteria:\n\n\\- Patients who have received anti-tumor treatment prior to PET\u002FCT scan. Suffer from severe other neurological diseases, or gastrointestinal, cardiovascular, liver, kidney, blood system, respiratory system, immunodeficiency and other serious diseases.\n\nAlternative subjects have contraindications to PET\u002FCT scanning. Including but not limited to: those who cannot tolerate repeated intravenous injections; those who may be allergic to the drug and its components (including those with a history of severe allergies or allergic reactions, especially those with allergies to the tested drug); claustrophobia.\n\nIn the past year, diagnosed with other malignant tumors; alternative subjects have undergone major surgery in the past 3 months; received experimental drug or device treatment with unclear effects or safety within the past month, or have participated in other interventional clinical trials.\n\nPregnant or lactating women. Patients who are lost to follow-up. Other conditions that, in the researcher's assessment, may affect the study or make the subject unsuitable for participation in the study.","75 Years",{"count":115,"type":20},[88],"This is a prospective, open-label, single-center clinical study targeting renal cell carcinoma. Sixty patients with a high clinical suspicion of renal cell carcinoma were included. Qualified subjects will undergo 68Ga-NOTA-RCCB6 PET\u002FCT examination. The aim is to establish the optimal imaging protocol; evaluate the distribution characteristics and correlations of physiological and pathological positive uptake, and using pathological results as the gold standard, assess the diagnostic efficacy of 68Ga-NOTA-RCCB6 PET\u002FCT in renal cell carcinoma.",[26],[183,184,185,186,187],"Renal cell cancer","PSMA","The cluster of differentiation (CD70)","Kidney tumor","ImmunoPET","2025-01-07",{"date":190,"type":35},"2025-01-10",{"date":192,"type":35},"2024-06-12",{"date":194,"type":20},"2025-11-07",{"name":196,"class":42},"Xijing Hospital"]